Novavax, Inc. (NASDAQ:NVAX) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 48.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 861,479 shares of the biopharmaceutical company's stock after purchasing an additional 280,381 shares during the quarter. BNP Paribas Financial Markets owned 0.73% of Novavax worth $4,135,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Commonwealth Equity Services LLC boosted its position in Novavax by 14.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 17,307 shares of the biopharmaceutical company's stock worth $125,000 after purchasing an additional 2,201 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in Novavax in the 3rd quarter worth approximately $212,000. Raymond James & Associates purchased a new stake in Novavax in the 3rd quarter worth approximately $1,021,000. Raymond James Financial Services Advisors Inc. purchased a new stake in Novavax in the 3rd quarter worth approximately $76,000. Finally, Bank of New York Mellon Corp boosted its position in Novavax by 3.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 364,532 shares of the biopharmaceutical company's stock worth $2,639,000 after purchasing an additional 13,326 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company's stock.

Novavax Stock Up 5.3 %

Shares of NVAX traded up $0.79 during midday trading on Wednesday, reaching $15.70. The company had a trading volume of 30,228,984 shares, compared to its average volume of 11,272,219. Novavax, Inc. has a 1-year low of $3.53 and a 1-year high of $17.40. The stock has a market cap of $2.20 billion, a PE ratio of -4.95 and a beta of 1.63. The firm has a 50 day simple moving average of $5.90 and a 200-day simple moving average of $5.33.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.01). The business had revenue of $93.90 million during the quarter, compared to analyst estimates of $71.32 million. During the same period in the previous year, the business earned ($3.41) earnings per share. The firm's revenue was up 15.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Novavax, Inc. will post -0.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on NVAX. JPMorgan Chase & Co. upgraded Novavax from an "underweight" rating to a "neutral" rating in a research report on Friday, May 10th. TD Cowen increased their target price on Novavax from $5.00 to $10.00 and gave the company a "hold" rating in a research report on Monday, May 13th. HC Wainwright reiterated a "buy" rating and set a $19.00 target price on shares of Novavax in a research report on Monday, May 13th. Finally, Bank of America upgraded Novavax from an "underperform" rating to a "neutral" rating and increased their target price for the company from $4.00 to $12.00 in a research report on Friday, May 10th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Novavax has an average rating of "Hold" and a consensus target price of $14.00.

Insiders Place Their Bets

In other Novavax news, insider Filip Dubovsky sold 47,312 shares of the firm's stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $13.90, for a total value of $657,636.80. Following the completion of the sale, the insider now directly owns 38,953 shares of the company's stock, valued at approximately $541,446.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.90% of the company's stock.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.